Investigating the cerebellum's role in time prediction using magnetic stimulation
Effects of the Magnetic Transcranial Stimulation (TMS) in Healthy Volunteers
This study is testing how the cerebellum helps healthy people predict time using magnetic stimulation to see if it can help us understand conditions like schizophrenia better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 48 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT04300946 on ClinicalTrials.gov |
What this trial studies
This study aims to explore how the cerebellum contributes to time prediction in healthy volunteers through the use of magnetic transcranial stimulation (TMS). Participants will undergo TMS targeted at the cerebellum while their behavioral responses related to time prediction are recorded. The study focuses on understanding the neural mechanisms underlying time perception, which could have implications for conditions like schizophrenia. By examining healthy individuals, the research seeks to establish a baseline for future studies involving patients with neurological disorders.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy volunteers aged 18 to 60 who are not currently using substances or have neurological disorders.
Not a fit: Patients with substance use disorders, neurological pathologies, or specific psychological conditions like ADHD may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of time perception mechanisms, potentially leading to improved treatments for schizophrenia.
How similar studies have performed: While this approach is relatively novel, similar studies using TMS have shown promise in understanding brain functions, though specific applications to time prediction are less explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant, male or female, between 18 and 60 years old * Subject affiliated to a social health insurance scheme (beneficiary or entitled person) * Subject who has dated and signed an informed consent form * For a woman of childbearing age, negative pregnancy test and effective contraception throughout the study Exclusion Criteria: * \- Participant with substance use disorders (as defined by DSM-V) * Participants taking benzodiazepines and related substances (in the period before inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (in the 2 months before inclusion) or hallucinogenic substances (in the period before inclusion, for a duration equivalent to 5 half-lives of the product). * Participant with neurological pathology or sequelae * Participant with Attention Deficit Hyperactivity Disorder (ADHD) * Participant with a borderline personality disorder * Participant with disabling sensory impairments, including visual acuity (corrected, if applicable) \< 0.8 (due to use of visual material) (Freiburg Vision Test, Bach 1996) * Participant deprived of liberty or subject to the safeguard of justice * Participant under guardianship or curatorship * Participant in a period of exclusion defined by another clinical study or participant in a study that may impact on research results * Pregnant or breastfeeding woman * Subject with a contraindication to performing an MRI or TMS: presence of non-removable ferromagnetic body, prosthesis, pacemaker, medication delivered by an implanted pump, vascular clip or stent, heart valve or ventricular lead, certain intracerebral clips, cochlear implants, history of epilepsy, skin pathology at the point of contact with the electrodes. * Subject with a history of major neurological or psychiatric illness with current psychotropic medication (i.e., antidepressant, thyroid regulator, antipsychotic, benzodiazepine and related drugs, or hypnotic).
Where this trial is running
Strasbourg
- CHU Strasbourg — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Anne Giersch
- Email: giersch@unistra.fr
- Phone: 000333
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.